Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23779185 | 0.85 | MEN1 (0.35) | MEN1KMT2ASLC6A3 | |
| SCHEMBL10352166 | 0.85 | MEN1 (0.35) | MEN1KMT2ASLC6A3 | |
| SCHEMBL28568866 | 0.84 | MEN1 (0.34) | MEN1KMT2ASLC6A3 | |
| SCHEMBL2074758 | 0.82 | SLC6A3 (0.35) | MEN1KMT2ASLC6A3 | |
| SCHEMBL23970494 | 0.81 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL29005522 | 0.80 | MEN1 (0.40) | MEN1KMT2ASLC6A3 | |
| SCHEMBL8374252 | 0.80 | MEN1 (0.40) | MEN1KMT2ASLC6A3 | |
| SCHEMBL3609772 | 0.78 | CYP4F2 (0.41) | MEN1KMT2A | |
| SCHEMBL24784170 | 0.78 | MEN1 (0.36) | MEN1KMT2ASLC6A3 | |
| SCHEMBL10384417 | 0.78 | MEN1 (0.42) | MEN1KMT2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112624943-B | Synthesis method of feloxicib intermediate | 成都伊诺达博医药科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-112624943-A | Synthesis method of feloxicib intermediate | 成都伊诺达博医药科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| US-8258122-B2 | 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives | ALMIRALL, S.A. (ES) | 2012-09-04 | — | — | US | disclosed |
| US-20100120731-A1 | 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| EP-2118100-A1 | NEW 3- ([1,2,4] TRIAZOLO [4,3-A] PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | Almirall, S.A. (ES) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008107125-A1 | NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120731-A1 | 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | MAP4K2, MAP3K7, MAPK7 | MEN1 4584/4885KMT2A 3575/4885SLC6A3 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.